Clinical trial
Vaccine Therapy Plus Immune Adjuvants in Treating Patients With Advanced…
NCT00003362 · Memorial Sloan Kettering Cancer Center, Other · Completed
Key facts
| NCT number | NCT00003362 |
|---|---|
| Title | Vaccine Therapy Plus Immune Adjuvants in Treating Patients With Advanced Melanoma |
| Official title | Pilot Trial of Multi-Epitope Melanoma Peptide Vaccine Using GM-CSF, Montanide and QS-21 as Adjuvants |
| Lead sponsor | Memorial Sloan Kettering Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Melanoma (Skin) |
| Intervention type | Biological |
| Interventions | QS21, gp100 antigen, incomplete Freund's adjuvant, sargramostim, tyrosinase peptide |
| Start date | May 1, 1998 |
| Primary completion | Feb 1, 2001 |
| Completion | Feb 1, 2001 |
| First posted | Aug 26, 2004 |
| Last update posted | Jun 25, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: